Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission

Leukemia

Volumn 13, Issue 3, 1999, Pages 386-392

  Feuring Buske, M ^a   Haase, D ^a   Buske, C ^a   Hiddemann, W ^a   Wormann B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

AML; CD34; CD38; Complete remission; Cytogenetics; MRD; Stem cells

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CHROMOSOME 16; CHROMOSOME 2Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA REMISSION; LEUKEMOGENESIS; PRIORITY JOURNAL; STEM CELL;

EID: 0033043610     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401300     Document Type: Article

References (36)

1. Fialkow PF, Singer JW, Adamson JW. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981; 57: 1068-1073.
2. Dick JE, Lapidot T, Pflumio F. Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev 1991; 124: 25-43.
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick J. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
4. Feuring-Buske M, Haase D, Könemann S, Troff C, Hiddemann W, Wörmann B. Trisomy 4 in the stem cell compartment of a patient with AML. A case report. Leukemia 1995; 9: 1318-1320.
5. Mehrothra B, George TI, Kavanau K, Avet-Loiseau H, Moore II D, Willman CL, Slovak ML, Atwater S, Head DR, Pallavicini MG. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 1995; 6: 1139-1147.
6. + subpopulations. Blood 1995; 86: 2906-2912.
7. Lim SH, Culligan D, Coutzens S, Fisher J, John S, Pollard P, Burnett A, Whittacker J. Molecular evidence for a common leukaemic progenitor in acute mixed lymphoid and myeloid leukaemia. Br J Haematol 1996; 2: 31-33.
8. + cells. Med Genet 1996; 8: 55-59.
9. Büchner T, Hiddemann W, Blasius S, Koch P, Maschmeyer G, Tirier C, Sodomann H. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. In: Büchner, Schellong, Hiddemann, Ritter (eds). Haematology and Blood Transfusion, Acute Leukemias II. Springer Verlag: Berlin, 1990, pp 261-266
10. Büchner T, Hiddemann W, Schaefer UW, Löffler G, Maschmeyer G, Ludwig WD, Aul C, Lathan B, Heinecke A. Combined effect of very early intensification and prolonged postremission chemotherapy in patients with AML. Leukemia 1992; 6: 68-70.
11. Anastasi J. Fluorescence in situ hybridization in leukemia. Applications in diagnosis, subclassification and monitoring the response to therapy. Ann NY Acad Sci 1993; 677: 214-224.
12. Brenner MK, Rill DR, Moen RC. Gene-marking trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
13. + T-lymphocytes in mobilized peripheral blood of t(8;21) AML M2 in complete remission. Blood 1996; 88: 562a, 2238.
14. Turhan AG, Lemoine FM, Debert C, Bonnet ML, Baillou C, Picard F, Macintyre EA, Varet B. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 5: 154-161.
15. Wörmann B. Implications of detection of minimal residual disease. Curr Opin Oncol 1993; 5: 3-10.
16. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171.
17. Wörmann B, Könemann S, Humpe A, Safford M, Zurlutter K, Schreiber K, Piechotka K, Büchner Th, Hiddemann W, Terstappen LWMM. Detection of residual leukemic cells in AML. In: W Hiddemann, Th Büchner, W Plunkett, M Keating, B Wörmann, M Andreev (eds). Haematology and Blood Transfusion - Acute Leukemias. Springer Verlag: Berlin, 1992; 34: 196-203.
18. Freireich EJ, Cork A, Sass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of MRD in acute myeloblastic leukemia. Leukemia 1992; 6: 500-506.
19. Nylund SJ, Ruutu T, Saarinen U, Larramendy ML, Knuutila S. Detection of minimal residual disease using fluorescence DNA in situ hybridization: a follow-up study in leukemia and lymphoma patients. Leukemia 1994; 8: 587-594.
20. Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-739.
21. Tobal K, Yin AL. Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996; 88: 3704-3709.
22. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Mandelli F, Lo Coco F. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse transcription polymerase chain reaction of the PML/RARa fusion gene. Blood 1997; 90: 1321-1325.
23. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci PG, Lo Coco F. Absence of reverse transcription polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82: 3556-3559.
24. Terstappen LWMM, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multidimensional flow cytometry. Anal Cell Pathol 1990; 2: 229-240.
25. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
26. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
27. Galtseva I, Miterev G, Paravitchnikova H, Kulikov S, Maslova H, Savchenko V. Detection of minimal residual disease in patients with acute myeloid leukemia. In: W Hiddemann, T Büchner, B Wörmann, J Ritter, U Creutzig, M Keating, W Plunkett (eds). Acute Leukemias VII. Springer Verlag: Berlin, 1997, pp 1012-1019.
28. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez W, Andreef M. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 1997; 99: 64-75.
29. Terstappen LWMM, Safford M, Unterhalkt M, Könemann S, Zurlutter K, Piechotka K, Drescher M, Aul C, Büchner Th, Hiddemann W, Wörmann B. Flow cytometric characterization of acute myeloid leukemia IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6: 993-1000.
30. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenetic analysis of hematopoiesis: III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antybody raised against KG-1 a cells. J Immunol 1984; 133: 157-165.
31. Civin CI, Trischmann TM, Fackler MJ, Bernstein ID, Bühring H, Campos L, Greaves MF, Kamoun M, Katz DR, Lansdorp PM, Look AT, Seed B, Sutherland DR, Tindle RW, Uchanska-Ziegler B. Report on the CD34 cluster workshop. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGKr (eds). Leukocyte Typing IV: White Cell Differentiation Antigens. Oxford University Press: Oxford 1990, pp 818-819.
32. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals of the classification of acute leukemias. A report of the French-American-British Cooperative Group. Br J Haematol 1976; 33: 451-458.
33. Büchner Th, Hiddemann W, Schaefer UW, Löffler G, Maschmeyer G, Ludwig WD, Aul C, Lathan B, Heinecke A. Combined effect of early intensification and prolonged postremission chemotherapy in patients with AML. Leukemia 1992; 6: 68-70.
34. ISCN. An International System for Human Cytogenetic Nomenclature. Birth Defects: Original Article Series No.1, Vol.21, National Foundation, March of Dimes, New York 1985.
35. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN. Gene marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Lancet 1993; 341: 85-86.
36. Deisseroth AB, Zu Z, Claxton D. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994; 83: 3068-3076.